摘要
非缺血型视网膜中央静脉阻塞(central retinal vein occlusion,CRVO)可导致黄斑水肿及视力下降,虽然玻璃体注射抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物有助于在短时间内减轻黄斑水肿,但对患眼视网膜静脉回流受阻引起的静脉瘀滞及视网膜中心静脉压(reti-nal central venous pressure,RCVP)升高并无作用.激光诱导的脉络膜视网膜静脉吻合(laser-induced chorioretinal venous anastomosis,L-CRVA)有助于视网膜静脉血经脉络膜引流,以降低RCVP并缓解视网膜静脉瘀滞.随着激光技术的发展,L-CRVA的成功率得以提升,相关并发症也得以减少.L-CRVA与抗VEGF联合使用使非缺血型CRVO的永久治愈成为可能,且有助减少患者的治疗负担.(国际眼科纵览,2024,48:129-132)
Abstract
Non-ischemic central retinal vein occlusion(CRVO)can cause macular edema and im-pairment of central vision.Intravitreal anti-VEGF therapy helps to reduce macular edema in CRVO,it does not work in venous stasis and elevated retinal central venous pressure(RCVP)caused by retinal venous re-turn distrubance.Laser-induced chorioretinal venous anastomosis(L-CRVA)is helpful for transchoroidal drainage of retinal venous blood to reduce RCVP and relieve retinal venous stasis.With the development of laser,the success rate of anastomosis formation has been improved and complications have been reduced.The combination of L-CRVA and anti-VEGF may permanently cure non-ischemic CRVO and help to reduce the burden of patients.(Int Rev Ophthalmol,2024,48:129-132)
NETL
NSTL
万方数据